News

Based on the FDA’s response, XTL plans to file its IND, and in the coming quarters initiate a global clinical trial for hCDR1 in the treatment of systemic

Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. Generic and brand sales of Retin-A, which is indicated for

Data generated from the analysis are expected to expand the understanding of multiple myeloma biology and potentially identify mechanisms of sensitivity or resistance to proteasome inhibitor treatment, which

This will allow researchers to develop automated cancer detection image analysis tools which can be easily distributed to research and clinical users. The platform will also support the

BOTOX is the first and only botulinum toxin product to be approved by the FDA to treat multiple muscle groups of the upper (elbow, wrist, fingers, and thumb)

Dyax is engaged in the development and commercialization of novel biotherapeutics for unmet medical needs. The company is developing DX-2930, a fully humanized monoclonal antibody targeting plasma kallikrein

A statistically significant improvement was demonstrated in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer. It is first phase 3 Vectibix trial

The company is now allowed to use Opdivo in combination with Yervoy (ipilimumab) to treat unresectable or metastatic melanoma across BRAF mutational status. The indication includes both BRAF-wild

Based on this review, the DSMB observed a continued acceptable safety and tolerability profile of Pyridorin in patients with overt diabetic nephropathy. NephroGenex CEO and President Pierre Legault